MRKR

Insider Trades

Name	Value	Action	Price	Last Price
Elms SteveDirector $35k11.1k shares BuyDec 23, 2024 $3.20 $1.31
New Enterprise Associates 16, L.P.10 Percent Owner $2M554.3k shares BuyDec 23, 2024 $3.20 $1.31

News

zacks.comMARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?zacks.comMay 20

Trade MRKR

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

CEO: Juan F. Vera
IPO Date: Jul 16, 2002

Market Data

Open: $1.37
High: $1.40
Low: $1.33
Volume: 46.6K
Avg Volume: 96.9K
52W High: $4.07
52W Low: $0.81

Valuation

Market Cap: $14.4M
Enterprise Value: -$554.5K
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$12M
Revenue: $0
Net Income: -$12.2M
Cash: $16.1M
Debt: $0

Events

EarningsAug 13

EPS est. -0.25